Bookmark and Share

This article is in the news archive.

The Milner Consortium call is open!

The Milner Therapeutics Consortium is excited announce its second call for research proposals, which is now open! The deadline for applications is 30th March 2022. 


Our pharma partners in the Milner Therapeutics Consortium are working together with academics at the University, Babraham and Wellcome Sanger Institutes to better understand disease mechanisms and to discover and validate new therapeutic targets. These pre-clinical projects range from reagent sharing and 6-month pilots, to 2-year postdoctoral funded collaborations and are expected to lead to joint publications with the company partners.


Key neuroscience themes include: 

  • Neurodegenerative disorders including genetic diseases with a neurodegenerative component 
  • Astrocyte biology 
  • Retinal degeneration, hearing loss 
  • Mood disorders, addiction, sleep disorders including apnoea 
  • Neuropathic and chronic pain 
  • Novel technologies and approaches to treat disease  
  • Target identification and validation to understand disease biology and/or facilitate therapeutic intervention  
  • Mitochondria, autophagy, UPR, lysosome biology (including ion channels), neuroinflammation, senescence, lipid homeostatsis,  
  • Crossing the blood brain barrier using novel chemical or biological entities 
  • Digital therapeutics 

Proposals from teams who are working across disciplines to apply new approaches to disease biology are particularly welcome. To learn more and download an application form, please see the Consortium Call websiteAlternatively, you can email Nicola McCarthy, our Consortium Manager, at 

Posted on 14/02/2022

Further news

Go to the news index page.